[1]孙瑶 杨志明.窦性心律心衰患者脑卒中风险评估的研究进展[J].心血管病学进展,2023,(6):528.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.011]
　SUNYao,YANG Zhiming.Risk of stroke in patients with heart failure and sinus rhythm[J].Advances in Cardiovascular Diseases,2023,(6):528.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.011]
点击复制

窦性心律心衰患者脑卒中风险评估的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年6期
页码:
528
栏目:
综述
出版日期:
2023-06-25

文章信息/Info

Title:
Risk of stroke in patients with heart failure and sinus rhythm
作者:
孙瑶1 杨志明 2
(1.山西医科大学第二临床医学院,太原 山西 030000;2.山西医科大学第二医院心内科,太原 山西 030000)
Author(s):
SUNYao1; YANG Zhiming2
(1.The Second Clinical Medical College of Shanxi Medical University,Taiyuan 030000,Shanxi,China; 2.Department of Cardiology,the Second Hospital of Shanxi Medical University,Taiyuan 030000,Shanxi,China)
关键词:
心衰; 窦性心律; 脑卒中; CHA2DS2-VASc评分; 口服抗凝药物
Keywords:
Heart failure; Sinus rhythm; Stroke; CHA2DS2-VASc score; Oral anticoagulants
DOI:
10.16806/j.cnki.issn.1004-3934.2023.06.011
摘要:
即使不合并房颤或心房扑动，心衰（HF）患者发生脑卒中及其他血栓栓塞事件的风险也会增加。目前指南推荐合并房颤的HF患者使用口服抗凝药物，然而预防性抗凝是否能使窦性心律HF患者获益尚不清楚。较早的随机试验指出华法林可降低此类患者缺血性脑卒中的发生率，该益处被高出血风险所抵消。然而这些试验包括了所有窦性心律HF患者，仍存在高脑卒中风险的患者亚群可能从抗凝治疗中获得临床净收益。现通过回顾和总结目前对窦性心律HF患者进行脑卒中风险分层的工具和方法，来识别可能从抗凝治疗中获益的患者亚群，权衡脑卒中和出血风险，考虑是否向患者推荐使用抗凝药物。
Abstract:
Patients with heart failure experience an increased risk of thromboembolic events including stroke,even without atrial fibrillation or flutter. Current guidelines recommend oral anticoagulants for patients when atrial fibrillation is present,however,the benefits of this therapy in patients with heart failure and sinus rhythm are unclear. Early randomized trials showed that warfarin reduced the incidence of ischemic stroke in patients with heart failure and sinus rhythm,but the benefits were offset by the higher blood risk. However,these trials included all patients with heart failure in sinus rhythm,and a subset of patients who remain at high risk for stroke may receive a net clinical benefit from anticoagulation. The purpose of this paper is to identify subgroups of patients who may benefit from anticoagulation by reviewing and summarizing current tools and methods for risk stratification of stroke in patients with heart failure and sinus rhythm. Clinical doctors may consider whether or not to recommend anticoagulation for these patients after weighing the risk of stroke and bleeding

参考文献/References:

1. Lardizabal J,Deedwania P. Atrial fibrillation in heart failure[J]. Med Clin North Am,2012,96(5):987-1000.

2. Borissoff J,Spronk HM,Heeneman S,et al. Is thrombin a key player in the ’coagulation-atherogenesis’ maze[J]. Cardiovasc Res,2009,82(3):392-403.

3. Adelborg K,Szépligeti S,Sundb?ll J,et al. Risk of Stroke in Patients With Heart Failure: A Population-Based 30-Year Cohort Study[J]. Stroke,2017,48(5): 1161-1168.

4. Scherbakov N,Haeusler KG, Doehner W. Ischemic stroke and heart failure: facts and numbers[J]. ESC Heart Fail,2015,2(1):1-4.

5. Rivas A,Lauw MN,Schnabel RB,et al. Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification[J]. Thromb Haemost,2022,122(6):871-878.

6. Lip GY,Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited [J]. J Am Coll Cardiol,1999,33(5):1424-6.

7. Lin AY,Dinatolo E,Metra M,et al. Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology,Pathophysiology,Clinical Trials,and Future Direction[J]. JACC Heart Fail,2021,9(4):243-253.

8. Kim W,Kim EJ. Heart Failure as a Risk Factor for Stroke[J]. J Stroke,2018,20(1): 33-45.

9. Zuchi C,Tritto I,Carluccio E,et al. Role of endothelial dysfunction in heart failure[J]. Heart Fail Rev,2020,25(1):21-30.

10. Santulli G. MicroRNAs and Endothelial (Dys) Function[J]. J Cell Physiol,2016,231(8): 1638-1644.

11. Havakuk O,King KS,Grazette L,et al. Heart Failure-Induced Brain Injury[J]. J Am Coll Cardiol,2017,69(12):1609-1616.

12. Derdeyn C,Videen TO,Yundt KD,et al. Variability of cerebral blood volume and oxygen extraction stages of cerebral haemodynamic impairment revisited [J]. Brain,2002,125(3):595-607.

13. Lorenzi-Filho G,Azevedo ER,Parker JD,et al. Relationship of carbon dioxide tension in arterial blood to pulmonary wedge pressure in heart failure[J]. Eur Respir J,2002,19(1):37-40.

14. Weber T,Wassertheurer S,O’Rourke MF,et al. Pulsatile hemodynamics in patients with exertional dyspnea: potentially of value in the diagnostic evaluation of suspected heart failure with preserved ejection fraction[J]. J Am Coll Cardiol,2013,61(18): 1874-1883.

15. Chou YL,Liou JT,Cheng CC,et al. The association of ischaemic stroke in patients with heart failure without atrial flutter/fibrillation[J]. Heart,2020,106(8):616-623.

16. Cokkinos DV,Haralabopoulos GC,Kostis JB,et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study[J]. Eur J Heart Fail,2006,8(4):428-432.

17. Pullicino PM,Thompson JL,Sacco RL,et al. Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial[J]. Cerebrovasc Dis,2013,36(1): 74-78.

18. Cleland JG,Findlay I,Jafri S,et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure[J]. Am Heart J,2004,148(1):157-164.

19. Massie BM,Collins JF,Ammon SE,et al. Randomized trial of warfarin,aspirin,and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial[J]. Circulation,2009,119(12):1616-1624.

20. Wolsk E,Lamberts M,Hansen ML,et al. Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study[J]. Eur J Heart Fail,2015,17(8): 828-836.

21. Marzouka G,Rivner H,Mehta V,et al. The CHADS-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation[J]. Am J Cardiol,2021,155: 72-77.

22. Mehra M,Vaduganathan M,Fu M,et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure,coronary artery disease,and sinus rhythm: the COMMANDER HF trial[J]. Eur Heart J,2019,40(44):3593-3602.

23. Melgaard L,Gorst-Rasmussen A,Lane DA,et al. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke,Thromboembolism,and Death in Patients With Heart Failure With and Without Atrial Fibrillation[J]. JAMA,2015,314(10):1030-1038.

24. Hai JJ,Chan PH,Chan YH,et al. Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry[J]. PLoS One,2016,11(12):e0169095.

25. Li J,Hidru TH,Yang X,et al. Risks of Ischemic Stroke/Transient Ischemic Attack Based on CHADS-VASc Scores in Non-Atrial Fibrillation Chinese Patients with Sinus Rhythm[J]. Int Heart J,2021,62(2):312-319.

26. Poli D,Antonucci E,Pengo V,et al. Comparison of HAS-BLED and HAS-BED Versus CHADS(2) and CHA(2)DS(2)VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation[J]. Am J Cardiol,2017,119(7):1012-1016.

27. Abdul-Rahim AH,Perez AC,MacIsaac RL,et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction,but without atrial fibrillation: analysis of the CHARMPreserved and I-Preserve trials[J]. Eur Heart J,2017,38(10):742–750.

28. Ferreira JP,Lam CSP,Anker SD,et al. Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial[J]. Eur J Heart Fail,2021,23(4):648-656.

29. Larsson SC,B?ck M,Rees JMB,et al. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study[J]. Eur Heart J,2020,41(2):221-226.

30. Saleh ZT,Lennie TA,Darawad M,et al. The health outcomes of inflammation and obesity in patients with heart failure[J]. Heart Lung,2020,49(6):896-901.

31. Park J,Hwang IC,Park JJ,et al. Left Atrial Strain to Predict Stroke in Patients With Acute Heart Failure and Sinus Rhythm[J]. J AM HEART ASSOC,2021,10(13):e020414.

32. Son MK,Lim NK, Park HY. Predicting stroke and death in patients with heart failure using CHA(2)DS(2)-VASc score in Asia[J]. BMC Cardiovasc Disord,2019,19(1):193.

33. Hopper I,Skiba M, Krum H. Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm[J]. Eur J Heart Fail,2013,15(1):69-78.

34. Zannad F,Anker SD,Byra WM,et al. Rivaroxaban in Patients with Heart Failure,Sinus Rhythm,and Coronary Disease[J]. N Engl J Med,2018,379(14):1332-1342.

35. Branch KR,Probstfield JL,Eikelboom JW,et al. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease[J]. Circulation,2019,140(7):529-537.

36. McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.

更新日期/Last Update: 2023-07-21